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Abstract
Familial hypercholesterolemia is an autosomal dominant disorder characterized by elevated levels of low density lipoprotein (LDL) carrying cholesterol in the blood. FH
is mainly caused by mutations in the gene encoding the low density lipoprotein receptor (LDLR) which causes altered lipid metabolism. LDLR is synthesized and initially
modified by glycosylation in the endoplasmic reticulum (ER) and transferred to the
plasma membrane by Golgi to carry out LDL clearance from the blood stream. Defective LDLR can therefore lead to increased levels of LDL in the blood which may lead
to atherosclerosis and premature coronary artery diseases.
For the past few years, cardiovascular diseases have been found to be the leading cause
of morbidity and mortality in UAE. In this study, the pathogenesis of a group of seven
missense LDLR variants (p. Cys167Phe), (p. Asp178Asn), (p. Glu277Lys), (p.
Gly314Arg), (p. His327Tyr), (p. Met652Thr) and (p. Arg814Gln) were evaluated and
identified in Emirati patients with suspected familial hypercholesterolemia (FH). The
aim of this project was to generate the identified missense LDLR variants in mammalian expression vector, establish their subcellular localization using confocal microscopy and evaluate their glycosylation status. It was found that several of these variants
resulted in an apparent partial retention of the LDLR mutants in the ER and hence their
possible failure to pass the ER quality control system. Several of the studied missense
mutants will be further studied in the future to investigate their exact pathogenicity
mechanism and cellular impact on the ER and endoplasmic reticulum associated protein degradation (ERAD).

Keywords: Familial Hypercholesterolemia (FH), Low Density Lipoprotein Receptor
(LDLR), Premature Coronary Artery Disease (CAD), Endoplasmic Reticulum
Associated Protein Degradation (ERAD), Endoplasmic Reticulum (ER).
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)Title and Abstract (in Arabic

األسس الخليوية للمتغيرات التي تسبب فرط كولسترول الدم العائلي في االمارات العربية
المتحدة
الملخص

فرط كولسترول الدم العائلي هو اضطراب وراثي سائد يتميز بمستويات مرتفعة من البروتين
الدهني المنخفض الكثافة الذي يحمل الكولسترول في الدم ينتج فرط كولسترول الدم العائلي بشكل
أساسي عن طفرة في جين مستقبالت البروتين الدهني المنخفض الكثافة والذي يتسبب في تغيير
التمثيل الغذائي للدهون يتم تصنيع مستقبالت البروتين الدهني المنخفض في الشبكة األندبلوزماية
ويتم نقله الى غشاء البالزما عن طريق جهاز جولجي إلزالة البروتين الدهني المنخفض .يمكن
أن تؤدي مستقبالت البروتين ال دهني المنخفض المعطلة الى زيادة في مستويات البروتين الدهني
المنخفض في الدم ويمكن أن يؤدي الى أمراض الشرايين التاجية المبكرة مثل تصلب الشرايين.
خالل العاميين الماضيين ،تم اكتشاف أمراض القلب واألوعية الدموية باعتبارها السبب الرئيسي
للوفيات في

دولة االمارات العربية المتحدة .في هذه الدراسة تم تحديد قائمة من الطفرات (p.

Cys167Phe), (p. Asp178Asn), (p. Glu277Lys), (p. Gly314Arg), (p. His327Tyr), (p.

) (p. Met652Thrو ) (p. Arg814Glnالمتسببة لفرط كولسترول الدم من مرضى إمراتيين .الهدف
من هذه األطروحة هو تصنيع هذه الالئحة من الطفرات ودراسة موقعها وحالتها داخل الخلية.
سيتم إجراء المزيد من الدراسات على الطفرات في المستقبل للتحقق من قدرتها المرضية وتأثيرها
البروتينات المرتبطة بالشبكة اإلندوبالزمية.

مفاهيم البحث الرئيسية :فرط كولسترول الدم العائلي ،مستقبالت البروتين الدهني المنخفض
الكثافة ،مرض شريان التاجي المبكر ،الشبكة االندوبالزمية المرتبطة بتدهور البروتين ،الشبكة
االندوبالزمية.
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Chapter 1: Introduction

1.1 Overview
Lipids are essential components that make up major constituents of the structure of the cell membrane as well as other cellular endomembranes. The plasma
membrane is an organelle that functions as a permeability barrier between the internal environment of the cell and the external environment (Ikonen, 2008). Also, it is
responsible for the diffusion of ions and solutes in and out of the cell and it maintains
electrical potentials (Ikonen, 2008). Furthermore, the cell membrane is a major site
for cellular signaling and communication. An important lipid ingredient that constitutes the mammalian plasma membrane is cholesterol.
1.2 Cholesterol: structure, biosynthesis and homeostasis
Cholesterol is one of the most important contents of the phospholipid bilayer
of the cell membrane as it makes up 20% to 25% of the lipid molecules such as glycolipids, sphingomyelin and a variety of phospholipids (Ikonen, 2008). A major function
of cholesterol is to provide fluidity to the cell membrane and creates a semi permeable
barrier between cellular organelles (Ikonen, 2008). In addition, it has an unequal distribution across cellular membranes giving the membrane a mosaic appearance
(Ikonen, 2008). Furthermore, cholesterol plays an important role in membrane trafficking and mediates numerous transmembrane signaling processes (Ikonen, 2008).
Cholesterol is a hydrophobic molecular and with a unique structural composition (Figure 1.1) constituting a four hydrocarbon ring called “steroid nucleus” as well as long
hydrocarbon tail made up of eight hydrocarbon chain (Soliman, 2018).
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Figure 1.1: Schematic diagram of the structural composition of cholesterol. Adapted
from PubChem Database (2020).

The structural composition of cholesterol allows an increase in its interaction
and cohesion with neighboring lipid molecules (Ikonen, 2008). The “steroid nucleus”
acts as a precursor for the synthesis of several steroid hormones such as Testosterone,
Progesterone, Estrogen and Vitamin D. In addition, steroids and bile acids are metabolites of cholesterol that perform as solubilizers and signal transducers of other lipids.
In humans, cholesterol is either synthesized endogenously by tissues and cells or provided exogenously from diet (Ikonen, 2008). Endogenously, cholesterol is de novo
synthesized mainly by the liver, intestine and reproductive organs through the mevalonate pathway (Soliman, 2018).
The improper composition of plasma membranes can lead to serious consequences which can result in altered cellular functions such as defective cellular signaling and protein trafficking (Ikonen, 2008). The overall cholesterol: protein ratio is correlated and highly vary depending on cell type and density (Ikonen, 2008). Accumulation and buildup of cholesterol in the arteries can the narrowing down of the arteries
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and eventually lead to coronary artery diseases such as atherosclerosis seen in Figure
1.2.

Figure 1.2: Comparison between a normal artery and an atherosclerotic artery.
Adapted from Topfer & Spry (2016).

However, cholesterol levels abnormalities can also cause defective cholesterol
storage monogenic disorders such as Familial Hypercholesterolemia (FH) and lysosomal cholesterol–sphingolipid storage diseases (Ikonen, 2008). In addition, cholesterol
has been shown to be involved in common conditions such as diabetes, cancer and
dementias (Ikonen, 2008). Cholesterol has an interesting physiological structure and
its importance in vertebrates and has fueled so many molecular and cellular research
activities in vitro and in vivo. Mostly, cell lines such as enterocytes, hepatocytes and
central nervous system cells were used to study cholesterol but animal models such as

4
mice remain more ideal, reliable and convenient to conduct research on cholesterol
homeostasis but not in studying atherosclerosis as mice contain cholesterol in circulating HDL (high density lipoprotein) which contributes to making mice resistant to atherosclerosis (Ikonen, 2008). As already mentioned, in humans circulating cholesterol
is either derived exogenously through a diet or endogenously through de novo synthesis via the mevalonate pathway (Figure 1.3). Moreover, there is a balance mechanism
through which the cholesterol levels in the blood are regulated and homeostasis maintained (Soliman, 2018). For example, when there are high levels of exogenous dietary
cholesterol, the de novo synthesis of cholesterol in the body is decreased (Soliman,
2018). De novo synthesis of cholesterol is performed by nucleated cells through the
mevalonate pathway starting from acetyl CoA (Ikonen, 2008) as shown in Figure 1.3.

Figure 1.3: Schematic diagram representing the biosynthesis of cholesterol which involves two pathways: Bloch pathway and Kandutsch- Russell pathway mainly starting with acetate and ending with cholesterol. Modified and adopted from Singh et al.
(2013).
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The first step of cholesterol biosynthesis demands the availability of O 2 and
operates under aerobic conditions by converting Lanosterol which is the first intermediate in the mevalonate pathway (Ikonen, 2008). The rate-limiting enzyme 3-hydroxy3-methyl-glutaryl-coenzyme A reductase (HMG-CoAR) catalyzes the reduction of 3hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) to mevalonate (Ikonen, 2008).
Both this reaction and sequential other reactions are catalyzed by integral ER membrane proteins (Ikonen, 2008). It is worth mentioning that the main used cholesterol lowering drugs such as statins do so by inhibiting the 3-hydroxy-3-methyl-glutarylcoenzyme A reductase (HMG-CoAR) enzyme.
In addition to cholesterol synthesis, triglycerides are continuously synthesized
by the liver using carbohydrates and free fatty acids as substrates. After the synthesis
of triglycerides, they are released by the liver and they reside in the core of the very
low density lipoprotein (VLDL) (Niu & Evans, 2011). VLDL undergoes structural
modifications involving the addition of apo protein B-48 along with apo proteins C
and E. Afterwards, lipoprotein lipase breaks down core triglycerides and converts
VLDL into intermediate-density lipoproteins (IDL) or remnant VLDL and release of
free fatty acids (Niu & Evans, 2011). During their circulation, some of the remnant
VLDL or IDL are eliminated by strongly binding to hepatocytes and the remaining
remnant VLDL or IDL are processed into LDL by substituting triglycerides into cholesterol esters, keeping the apo protein B and removing the other apo proteins shown
in Figure 1.4 (Niu & Evans, 2011).
On the other hand, dietary or exogenous cholesterol is absorbed by the gut and
transferred to the liver and then secreted into the blood stream and the lymph system
(Ikonen, 2008). Enterocytes and hepatocytes take up cholesterol and repackage it into
a more transportable form of lipoproteins that vary in composition and are modified
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through the circulation in the body (Ikonen, 2008). Basically, dietary cholesterol is
first absorbed and packaged into chylomicrons with triglycerides by the enterocytes of
the small intestine (Ikonen, 2008). Chylomicrons are transformed into chylomicron
remnants through the hydrolysis of triglycerides and coupling of new apoproteins such
as apoE (Ikonen, 2008). Hepatocytes in the liver absorb chylomicron remnants and
produce lipids packaged into very low density lipoproteins (VLDL) where it gets metabolized into intermediate density lipoprotein (IDL) and is eventually metabolized
into low density lipoprotein (LDL) as shown in Figure 1.4 (Ikonen, 2008).

Figure 1.4: Schematic representation of the exogenous and endogenous pathways of
cholesterol. Adapted from Karam et al. (2017).

Lipoproteins are classified into different classes such as chylomicrons, very
low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), high density
lipoprotein (HDL) and low density lipoprotein (LDL) (Sima et al., 2018). The common
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general structural characteristics of these lipoproteins is a spherical shape made up of
lipid cores containing different portions of cholesteryl esters, triglycerides and cholesterol as well as a coat of phospholipids and different Apo lipoproteins (Soliman, 2018).
However, the composition and quantities of triglycerides, Apo proteins and cholesterol
esters may vary from particle to particle due to a cascade of interactions through their
circulation involving several enzymes such as hepatic triglyceride lipase (HTGL), lecithin-cholesterol acyltransferase (LCAT), lipoprotein lipase (LPL), and cholesteryl ester transfer protein (CETP) (Dominiczak & Caslake, 2011). Due to cholesterol’s insolubility, it cannot be circulated freely in the blood stream and thus is packaged into a
more transportable particles called low density lipoprotein (LDL) where most of the
cholesterol molecule is esterified into cholesterol esters (Sima et al., 2018). The LDL
particles are captured by low density lipoprotein receptors (LDLR) on the surface of
some cell types and the LDL- LDLR complex is engulfed by the cell through a process
called endocytosis (Go & Mani, 2012). The internalized LDL-LDLR complex is carried into endosomes, hydrolyzed by lysosomes, LDL liberated into the cytoplasm
while LDLR is recycled back to the surface of the cell membrane (Go & Mani, 2012).
A defect in the clearance of LDL by LDLR can cause build up and narrowing
of cholesterol in the arteries causing premature coronary artery diseases such as atherosclerosis as illustrated in Figure 1.10 Basically, when LDL levels are elevated in the
blood, they undergo oxidation resulting in oxidized LDL (Ox-LDL) (Sima et al.,
2018). Consequently, Ox-LDL leads to constant adherence and accumulation to the
arterial walls and causes continues chronic inflammation (Sima et al., 2018).
1.3 Lipoproteins: diversity and composition
The composition and functions of the various cellular lipoproteins and some of
their protein components are summarized in the following sections:
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1.3.1 Chylomicrons
Out of all the mentioned lipoproteins, chylomicrons are the largest in terms of
their size, the rate at which they are absorbed and the type of fat absorbed (Julve et al.,
2016). Chylomicrons are composed of a lipid core mostly made out of 85-92% of
monoglycerides and triglycerides, 6-12% of phospholipids, 1-3% of free and esterified
cholesterol as well as a very small amount of fatty acids (Julve et al., 2016). One of
the most important ingredients in a chylomicron particle are the apo lipoproteins making less than 2% of chylomicrons (Julve et al., 2016). For chylomicrons, apo lipoproteins B48 determines a chylomicrons metabolic destiny and plays a crucial role in chylomicrons biosynthesis and production (Julve et al., 2016).
1.3.2 Very low density lipoprotein (VLDL)
Very-low-density lipoprotein (VLDL) are mainly composed and enriched with
triacylglycerol (TAG). VLDL synthesized and secreted by parenchymal liver cells
(Niu & Evans, 2011). VLDL is one of the five major lipoproteins and is comprised of
a central core of hydrophobic TAG as well as cholesteryl esters which are coated with
a hydrophilic monolayer of phospholipids and apolipoprotein B100 (Apo B100)(Niu
& Evans, 2011). TAG contained in VLDL’s core is made using endogenous fatty acid
sources that are derived from lipolysis in adipose tissues, hepatic de novo lipogenesis
and hydrolysis of plasma lipoprotein (Niu & Evans, 2011). Thus, VLDL performs as
a redistributor of endogenous lipids derived from the liver to cells in peripheral tissues
(Niu & Evans, 2011).

9
1.3.3 Low density lipoproteins (LDL)
Out of all the lipoprotein molecules, LDL is considered to be the most harmful
and dangerous lipoprotein for health (Sima et al., 2018). Lipoproteins are packaged by
complex Apo lipoprotein molecules that surface cell membranes shown in Figure 1.5
and interact with particular expressed receptor cell membrane proteins (Sima et al.,
2018).

Figure 1.5: Schematic drawing and predication of the structure of low density lipoprotein (LDL). Adapted and modified from Goldstein et al. (2001).

LDL is a spherical molecule with a diameter of 220 nm built up of a hydrophilic or
amphipathic monolayer coat of phospholipids and un-esterified cholesterol as well as
a hydrophobic core made of esterified cholesterol (Mateu et al., 1972). The hydrophilic
coat of LDL contains a hydrophobic type of apo proteins specifically apo-B which
facilitates the binding of LDL to LDL receptors. LDL’s predominant role is to deliver
and provide peripheral cells with cholesterol where needed (Ikonen, 2008). The
amount of liberated cholesterol from LDL has been set to regulate cholesterol’s homeostasis via three mechanisms: first, it reduces the expression of enzyme 3-hydroxy-3
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methylglutaryl coenzyme A (HMG-CoA) reductase when LDL-C increases in the cell
which alters intracellular cholesterol synthesis. Secondly, LDL cholesterol can initiate
the activation of another enzyme which in turn improves the storage of cholesterol in
the cell. Lastly, high levels of cholesterol stimulate a negative feedback process which
reduces the generation of LDL receptors (Cox & García-Palmieri, 1990).
1.3.4 High density lipoprotein (HDL)
HDL is the tiniest and heaviest lipoproteins out of all five lipoproteins
(Yetukuri et al., 2010). It is 5-17 nm in size and weighs 1.063-1.210 kg/l (März et al.,
2017). One of the major protein constituents in HDL is apolipoprotein (Apo AI) and
apolipoprotein (Apo AII) (Yetukuri et al., 2010) (Kosmas et al., 2018). Apo AI makes
up to 70% of the overall composition of an HDL molecule compared to Apo AII which
makes up to 20% of an HDL molecule only (Kosmas et al., 2018). In cases where
cholesterol is in excess, it is transported to the liver by HDL in a pathway referred to
as reverse cholesterol transport (RCT) (März et al., 2017). Also, LDL plays a role in
RCT (März et al., 2017). RCT is a process through which cholesterol is transferred
from peripheral tissues into blood circulation and is finally discarded in feces. HDL
has the power not to only being a cholesterol acceptor and play “the good cholesterol”
but also as a cholesterol transporter in RCT pathway as well as sending cholesterol to
the liver (Ouimet et al., 2019).
1.3.5 Apo lipoproteins (Apo)
As previously mentioned, the action of enzymes such as hepatic triglyceride
lipase (HTGL), lecithin-cholesterol acyltransferase (LCAT), lipoprotein lipase (LPL),
and cholesteryl ester transfer protein (CETP) are modulated by apo lipoprotein which
determine a lipoprotein conformation and structure (Dominiczak & Caslake, 2011).
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The predominant role of apolipoproteins is to regulate the ligand-receptor binding of
lipoproteins to their designated lipoprotein receptors. Apolipoproteins such as apolipoprotein E (apoE) and apolipoprotein B100 (apoB100) bind with LDL receptors that
recognize apoE and apoB100 (Dominiczak & Caslake, 2011). Also, apoE can specifically bind with another family of LDLR which are the low density related protein receptors (LRP) (Dominiczak & Caslake, 2011).
1.3.6 Apolipoprotein B100 (ApoB100)
ApoB100 has a molecular mass of 555,000 Da and decreases to 513,000 Da
when it is cleaved at the N terminal end. ApoB100 is made up of 4536 amino acids
and produced by hepatocytes. A defective apoB100 can lead to impaired ligand- receptor binding and can lead to a genetic disorder known as familial defective apoB
(FDB). ApoB can be found in both VLDL and LDL at a ratio of one apoB molecule to
one lipoprotein molecule (Dominiczak & Caslake, 2011).
1.3.7 Apolipoprotein B48 (ApoB48)
ApoB48 is produced by enterocytes and has a molecular mass of 264,000 Da
and is made up of 2152 amino acids (Dominiczak & Caslake, 2011). ApoB48 and
apoB100 are synthesized by a single gene but apoB48 is a truncated form of apoB100
(Dominiczak & Caslake, 2011). At the molecular level, cytidine nucleotide 6666 gets
deaminated and is transferred a uridine during apoB mRNA editing process which results in a stop codon (Dominiczak & Caslake, 2011). The stop codon is what makes
apoB48 (Dominiczak & Caslake, 2011). ApoB48 is inserted into chylomicrons and
they also remain in chylomicron’s remnants (Dominiczak & Caslake, 2011). A molecule of apoB48 is equal to one molecule of chylomicrons (Dominiczak & Caslake,
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2011). However, since apoE48 doesn’t have an LDL-receptor binding domain, chylomicron remnants are captured by apoE possessing LRP and LDL receptor binding domains (Dominiczak & Caslake, 2011). It has been studied that, particles having sizes
lesser than 70–80 nm can diffuse through vascular walls (Dominiczak & Caslake,
2011). Hence, nascent chylomicrons cannot penetrate through vascular walls while
chylomicron remnants can (Dominiczak & Caslake, 2011). So, chylomicron remnants
are considered atherogenic since they are rich in cholesteryl esters that are brought up
through exchange with HDL during chylomicron remnants circulation in the body
(Dominiczak & Caslake, 2011).
1.3.8 Apolipoprotein AI (Apo AI) and Apolipoprotein AII (Apo AII)
Apolipoprotein AI (Apo AI) is Apo AI is the major protein found in HDL
(Julve et al., 2016). Also, chylomicrons assembled and secreted from the intestine have
been found to be composed of considerable quantities of apo AI (Julve et al., 2016).
Apo AI is first synthesized by the ER and is later carried to the Golgi apparatus in the
form of vesicles for modification where apo AI is added to the mature chylomicron
particles before its release from the cells (Julve et al., 2016).
On the other hand, Apolipoprotein AII (Apo AII) is a produced by the liver,
has a molecular mass of 17,400 Da and has a homodimer structure made up of 77
amino acids (Dominiczak & Caslake, 2011). It makes up approximately 20% of the
total HDL pool (Dominiczak & Caslake, 2011).
In summary, there are many types of lipoprotein with variable composition,
size and function and some of their properties are listed in Table 1.1.
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Table 1.1: List of different types of lipoproteins, structural composition and their
constituents. Adapted from Goldstein (2001).
Lipoprotein

Size (Å)

Density C

particle
Chylomicrons

800-5000

0.95

TG

PL

ApoP

Apolipopro-

%

%

%

%

tein

3

90

5

9

AI, AII, B,
CI, CII, CIII

VLDL

300-800

0.95-

10

70

10

10

1.006
IDL

250-350

1.006-

BI, CI, CII,
CIII, E

-

-

-

-

B, CIII, E

26

10

15

25

B

20

5

25

50

AI, All

1.019
LDL

180-280

1.0191.063

HDL

50-120

1.0631.210

Table 1.1 abbreviations: C: cholesterol, TG: triglycerides, PL: phospholipids, ApoP: apoprotein

1.4 Low density lipoprotein receptor (LDLR): structure and function
Low density lipoprotein receptor (LDLR) is embedded in the cell membrane
and it functions in the clearance of LDL containing cholesterol particles (Go & Mani,
2012). The LDLR also plays a role in maintaining cholesterol homeostasis as well as
lipid and lipoprotein metabolism in mammals. LDLR is a cell membrane glycoprotein
that functions in the binding and internalizing of circulating cholesterol-containing lipoprotein particles. LDLR is ubiquitously expressed and is a key receptor for maintaining cholesterol homeostasis in mammals (Go & Mani, 2012). It is first synthesized as
an immature and inactive ER precursor glycoprotein of 120 kDa containing the core
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sugar (Nacetylgalactosamine) of the O-linked chains and high-mannose N-linked carbohydrate chains and is translocated to the Golgi complex where it gets further glycosylated into the mature form with 160 kDa molecular weight (Ashavaid et al., 2000).
As discussed earlier, LDL particle is composed of an extremely important protein
apoB100 which is essential for the recognition of LDL by LDLR. The mature form of
LDLR located in the cell plasma membrane identifies the circulating LDL particle and
internalizes as shown in Figure 1.6 through endocytosis in the form of clathrin coated
pits (Go & Mani, 2012). LDLR adaptor protein 1 (LDLRAP1) and disabled homolog
2 (Dab2) mediate the clustering of the LDL- LDLR complex into clatherin-coated pits
by interacting with the cytoplasmic tail of LDLR. Once the ligand-receptor complex
is internalized into the cell, clatherin detaches and vesicles fuse into the endosomes
where LDL- LDLR dissociate due to the difference in pH created by ATP driven proton pumps (Go & Mani, 2012). Once the ligand-receptor complex is dissociated, the
LDL particles are transported to the lysosomes and are degraded by hydrolytic lysosomal enzymes while LDLR is recycled back to the cell membrane in a vesicle alone to
repeat the cycle (Go & Mani, 2012). LDLR has a 20-hour life span and it therefore can
carry out multiple rounds of endocytosis (Brown & Goldstein, 1986). During LDL’s
internalization into the cell, it stimulates three mechanisms: first, it decreases the expression of 3- hydroxyl-3-methylglutaryl-coA reductase enzyme which in turn causes
a decrease in endogenous cholesterol synthesis (Go & Mani, 2012). Secondly, LDL
increases the degradation of toxic unusable cholesterol through increasing acyl-coA
cholesteryl acyl transferase (ACAT) activity. Lastly, LDL also inhibits the synthesis
of LDLR to decrease the clearance of LDL through SREBPs (Go & Mani, 2012).
Sterol regulatory element binding protein (SREBP) is essential for regulation of
LDLR’s transcription (Zhang et al., 2016).
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Figure 1.6: Schematic diagram of LDLR’s synthesis, pathway and function. Adapted
from Goldstein et al. (2001).
LDLR is first transcribed and processed in the nucleus. (1) It is translocated from the nucleus as precursor LDLR
with a molecular weight of 120 KDa and is synthesized and folded in the ER into its immature form of 120 kDa

molecular weight. (2) LDLR is then extensively glycosylated into the mature 160 kDa for in the Golgi
apparatus. Mature form of LDLR is transported in a vesicle to the cell membrane where it can perform
its function. (3) LDLR binds with LDL. (4) LDLR internalizes LDL molecules into the cel l through
endocytosis and clatherin-coated vesicles start to form to contain the LDLR-LDL complex and are
then delivered to endosomes (5) Due to the acidic environment in the lysosomes, LDLR-LDL
complex dissociates. The LDL particles reach the lysosomes an d are hydrolyzed whereas the LDLR is
recycled back to the cell membrane for another cycle.

1.4.1 LDLR structure
LDLR is a transmembrane receptor glycoprotein encoded by the gene LDLR.
According to Uniprot (Bateman, 2019), LDLR possess a molecular mass of 95,376 Da
and is made up of 18 exons, spans 45 kb on the short arm of chromosome19p13.2 and
is made up of 2583 nucleotides which are transcribed and translated into 861 amino
acids including a signal sequence of 21 amino acids that is cleaved during translocation
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of LDLR to the ER for modification (Go & Mani, 2012). The mature form of LDLR
is composed of five distinct domains (Figure 1.7) as the following:

Figure 1.7: Schematic diagram of LDLR domain structure and the corresponding exons in its gene. It demonstrates five distinct domains that compose the structure of a
mature LDLR. Adapted from Goldstein et al. (2001).

1) First domain is the LDLR binding domain (LBD) located on the N-terminal
end of the receptor and is made up of 292 amino acids (Südhof et al., 1985).
It provides stability for LDLR and plays a crucial role in the recognition of
LDL to LDLR through the interaction of short negatively charged amino
acids (Ser-Asp-Glu) in LBD binding with positively charged residues of
apoE and apoB in the LDL particle (Uribe et al., 2018). It is composed of
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seven repeats (LR1-LR7) indicated as each containing 40 residues (Uribe
et al., 2018). There are six cysteine residues per repeat in the LDLR binding
domain and they are all held together by disulphide bonds. Exons 2, 3, 5
and 6 encode for repeats 1, 3, 6, and 6 respectively while the rest of the
repeats are encoded by exon 4 (Südhof et al., 1985).
2) EGF precursor domain is the second domain in the LDLR which is encoded
by exons 7 to 14 and is comprised of 400 amino acids (Südhof et al., 1985).
EGF domain is involved in the release of the LDL- LDLR complex in the
endosome due to pH change. The EGF precursor domain is composed of
three repetitive 40 amino acids repeats including EGF A, EGF B and EGF
C (Südhof et al., 1985). EGF A mainly reacts with proprotein convertase
subtilisin/kexin type 9 (PCSK9). PCSK9 plays a role in regulating LDLR’s
homeostasis (Varret & Rabes, 2012). It binds to LDLR on the surface of
the cell membrane and degrades them (Varret & Rabes, 2012). It has been
implicated that gain of function mutations can cause a decrease in LDLR
quantities due to an increase in affinity between PCSK9 and LDLR hence
degrading more LDLR and leading to an increase in levels of LDL in the
blood (Varret & Rabes, 2012). Gain of function mutations cause a metabolic disorder called autosomal dominant hypercholesterolemia. However,
loss of function of PCSK9 causes a reduction in affinity between PCSK9
and LDLR hence, causing decreased levels of LDL in the blood (Varret &
Rabes, 2012). Furthermore, the first two repeats (EGF A and EGF B) are
separated from the third repeat (EGF C) by a multiple sequence of 280
amino acids each 40 -60 amino acid sequences is separated by a conserved
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motif (YWTD) referred to as the β-propeller region (Varret & Rabes,
2012).
3) O- linked sugars domain is the third domain encoded by exon 15 and plays
a major role in the post translational modification of LDLR (Varret &
Rabes, 2012). They are enriched with serine and threonine residues which
serve as attachment of O-linked sugar chains and allows LDLR to expand
into the extracellular space (Gent & Braakman, 2004). Due to the differences in acidity in the cellular compartments, glycosylation helps in preventing denaturation and stability of the immature LDLR during its translocation to different organelles in the cell (Gent & Braakman, 2004). Also,
it can possibly prevent LDLR’s proteolytic cleavage by metalloproteases
(Gent & Braakman, 2004).
4) Domain four is referred to as the membrane-anchoring domain or the transmembrane domain. It keeps the LDLR fully attached to the cell membrane
by serving as an attachment site (Varret & Rabes, 2012). This domain constitutes 22 hydrophobic amino acids and is coded by exon 16 and the 5’ end
of exon 17 (Varret & Rabes, 2012).
5) Exons 17 and 18 codify for the cytoplasmic tail which mediates Endocytosis of LDLR-LDL complex. The cytoplasmic tail is 50 amino acids long
(Varret & Rabes, 2012).
1.5 Mutations in LDLR are a major cause of Familial Hypercholesterolemia
Familial Hypercholesterolemia (FH) is an inherited metabolic disorder of defected lipoprotein metabolism and behaves in an autosomal dominant manner. FH occurs due to mutations mainly in the LDLR gene which causes a decrease in cholesterol
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catabolism (Benito-vicente et al., 2018). Worldwide, there are more than 90% reported
mutations and cases in FH are caused by defected LDLR (Austin et al., 2004).
FH can also be autosomal recessive as well and it is caused by mutations in
genes other than LDLR such as PCSK9, apoB both constituting between 1% and 5%
of mutations. PCSK9 variants are divided into two: (1) gain of function which means
the recycling pathway of LDLR is disrupted leading to rapid degradation of LDLR by
lysosomes reducing the numbers of LDLR on the cell membrane hence, LDL levels
elevated. (2) loss of function which means more degradation of LDL. Mutations in
apoB can cause impaired affinity between LDL and LDL hence, LDLR won’t be able
to identify LDL molecules. Lastly, low density lipoprotein receptor adaptor protein 1
(LDLRAP1) make up less than 1% of mutations and it causes autosomal recessive
familial hypercholesterolemia (ARH) (Benito-vicente et al., 2018). ARH is milder in
severity and has less visible phenotype than autosomal dominant familial hypercholesterolemia (ADH). Clinically, FH is characterized by the appearance of skin lesions
knows as tendons xanthomas (Figure 1.8), grey outline in the iris called corneal arcus
(Figure 1.9), elevated levels of cholesterol in the blood and a history of premature
coronary artery diseases (CAD).

Figure 1.8: Tendon Xanthomas. Adapted from Harada-Shiba et al. (2018)
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Figure 1.9: Corneal Arcus. Adapted from Harada- Shiba et al. (2018).

Figure 1.10: The consequences caused by pathogenic LDLR mutants which lead to
premature coronary artery disease known as atherosclerosis. Modified and adapted
from Nordestgaard et al. (2013).
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FH is a common genetic disease but often can be fatal if remained underdiagnosed. As mentioned, elevated levels of cholesterol can deposit on the walls of arteries
and cause (CAD) such as atherosclerosis as represented in Figure 1.10.
FH can occur in a homozygous manner and can occur in a heterozygous manner. FH homozygous (HoFH) patients have a higher exposure of CAD compared to
FH heterozygous patients (HeFH). Previously, it has been reported that the prevalence
of (HoFe) patients in people was 1: 106 people but recently, it has been reported that
the prevalence is 1: 300,000. On the other hand, (HeFH) patients have a higher prevalence between 1: 200 or 1:300 people (Benito-vicente et al., 2018). Worldwide, there
are more than 90% reported mutations caused by defected LDLR (Austin et al., 2004).
According to HGMD database (Stenson et al., 2014), there a total of 2286 variants that have been reported for LDLR classified as pathogenic or non-pathogenic and
range between point mutations, missense mutations, non-sense mutations, deletions,
insertions or duplications.
The LDLR FH-causing mutations have been classified into six functional classes as illustrated in Figure 1.11 and summarized here:
1) Class I mutants are generated when LDLR is not being synthesized
properly or no LDLR is being synthesized at all. No LDLR precursor
is being generated or LDLR transcript doesn’t exit the nucleus
(Ashavaid et al., 2000). There are few reasons why LDLR is not being
synthesized. 1) it could be due to missense/ point mutations in the promotor sequence of LDLR. 2) incorrect mRNA processing. Class 1 are
indicated “Null alleles” (Ashavaid et al., 2000).
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2) Class II are classified as “Transport-defective Alleles”: involves slow
trafficking of the LDLR precursor to ER/ ER to Golgi apparatus or improper folding and retention of LDLR in the ER (Ashavaid et al., 2000).
Class II may happen due to a defect in manufacturing LDLR which
resulted in a premature stop codon that lead to the synthesis of a truncated LDLR (Ashavaid et al., 2000). Also, another possibility could be
the absence of some cysteines in some cysteine binding domains and
thus causes a complete retention in the ER stimulating ER stress and
activating ERAD machinery (Ashavaid et al., 2000).
3) Defective binding of LDL to LDLR is class III and are referred to as
Binding-defective Alleles (Ashavaid et al., 2000). Despite its complete
post translational modification, in this class, LDLR lacks the affinity to
bind with LDL (Ashavaid et al., 2000).
4) The fourth class of LDLR variants are endocytosis defective variants.
Complete binding of LDLR to LDL but the cell’s incapable of taking
up the complex into clatherin coated clusters (Ashavaid et al., 2000). It
may be due to mutated or deleted domains in the LDLR structure particularly the transmembrane (4th) and cytoplasmic tail (5th) domains in
LDLR (Ashavaid et al., 2000).
5) Deletions in the EGF precursor domain are class V (Ashavaid et al.,
2000). The fifth class of LDLR mutants happens when there is a mutation or a complete deletion of EGF precursor domain which results in
complete internalization of LDL- LDLR complex but the dissociation
of LDLR and LDL in endosomes fails to take place. Hence, LDLR gets
degraded with the LDL in the lysosomes (Ashavaid et al., 2000). LDLR
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in this class isn’t recycled back to the surface. Class V are known as
Recycling-deficient Alleles (Ashavaid et al., 2000).
6) Class VI has been recently discovered and basically happens due to incomplete attachment of mature LDLR in the cell membrane caused by
mutations in the domain responsible for anchoring LDLR in the cell
membrane which is the cytoplasmic tail (Ashavaid et al., 2000).

Figure 1.11: Elucidates the different LDLR variant classes. Adapted from Hovingh et
al. (2013).

The above listed LDLR mutant classes can cause a metabolic disorder known
as Familial Hypercholesterolemia (FH) which inherited in an autosomal dominant
manner (Südhof et al., 1985).
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1.6 Cardiovascular disease and hypercholesterolemia in UAE
Familial Hypercholesterolemia is a metabolic disorder than has been studied
for the past decades. There are a total of 2286 variants causing FH reported by HGMD
(Stenson et al., 2014) worldwide. The disease is still being studied and mutations are
still being discovered. According to HGMD, most of those mutations are caused by
LDLR gene. However, FH remains underdiagnosed and underestimated. Cascade
screening is usually performed to identify FH patients through genetic testing and cholesterol testing. Once an FH patient is identified, first degree relatives are screened and
thereby expanding the number of cases to be studied and helps in the early diagnosis
of FH (Dias & Peng, 2017). However, there are some countries especially MENA
region were cascade screening is unavailable which makes it difficult to identify FH
cases and its molecular causes (Al-Mazrooei, 2008). Immigration is one of the causes
of FH in North American and Western European countries due to Arab ancestry. In
the MENA region, several mutations causing FH were discovered in Iraq, Algeria,
Kuwait, Morocco, Palestine, Bahrain and Syria. However, FH was extensively studied
in Arab countries such Lebanon, Tunisia and UAE. Amongst all Arab countries, in
1995, UAE has been found to have the highest prevalence of FH as reported by M.
Agrawal and his colleagues. One of the major causes contributing to FH in the MENA
region is consanguineous marriages (Al-Mazrooei, 2008).
Cardiovascular diseases such as coronary artery diseases cause a huge threat
on Arab countries such as UAE being the highest cause of death in the country. In
2004, it has been estimated that UAE’s population was around 4.3 million citizens (AlMazrooei, 2008). Out of the 4.3million people in UAE, 3 million were expatriates.
UAE is a developing and diverse country harboring many nationalities and ethnic
backgrounds (Al-Mazrooei, 2008) . 50% are South Asians, 23% are Iranian and Arabs,
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19% of them are Emiratis, and the rest 8% are East Asians and Westerners. Over the
years, UAE has been rapidly evolving and changed into a more luxurious life. Due to
this change and development, new diseases started to emerge due to the availability of
unhealthy food and lack of exercise (Al-Mazrooei, 2008). In 2000, UAE has witnessed
the highest morbidity and mortality rates. Cardiovascular diseases had the highest peak
of morbidity and mortality in UAE having the highest death rate of 25.4%. The most
important factors that contribute to cardiovascular diseases are genetics, hyperlipidemia and smoking. Basically, hyperlipidemia is an increase of lipids in the blood.
Cholesterol blood levels and their severity are classified in Table 1.2.

Table 1.2: Cholesterol blood levels and their clinical classifications in terms of
severity.
LDL levels (mg/dL)

Classification

>200 (>5.17 mmol/L)

Mild hypercholesterolemia

200-240 (5.17- 6.18 mmol/L)

Moderate hypercholesterolemia

>240 (>6.21 mmol/L)

Severe hypercholesterolemia

Although it is evident that CVDs are prevalent in UAE, but the underlying
molecular causes are not well established. Therefore, this project has been initiated to
elucidate the molecular and cellular basis of FH in among Emiratis in collaboration
with Imperial College London Diabetes Center in Abu Dhabi Dr Hinda Daggag, Dr
Maha Barakat and Groningen University in the Netherlands. Together, they have identified a list of LDLR missense variants in Emirati patients with suspected FH. The
following are some of the variants they have identified: (p. Cys167Phe), (p.
Asp178Asn), (p. Glu277Lys), (p. Gly314Arg), (p. His327Tyr), (p. Met652Thr) and (p.
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Arg814Gln). Therefore, the aim of this MSc research project is to investigate the pathogenicity of some of the identified variants in the LDLR gene in Emirati patients with
hypercholesterolemia and to delineate the cellular effects of the listed variants in
LDLR which may potentially help in designing and developing new therapeutic strategies.
In this project, cellular models using mammalian constructs of wild type and
mutant LDLR were generated to study the subcellular localization of the LDLR mutants compared to the wild type as well as to study processing and post transitional
modification of LDLR mutants and compare them wild type.
The specific objectives of this project are:
1) Generate the LDLR missense variants found in Emirati patients with suspected
FH using site directed mutagenesis with a mammalian expression vector as
template.
2) Express the wild type and the generated LDLR variants in mammalian cells
(HeLa and HEK2933).
3) Establish the subcellular localization of the mutant proteins relevant to wild
type using confocal fluorescence microscopy.
4) Evaluate the glycosylation profiles of the mutants and compare them to wild
type.
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Chapter 2: Methods
2.1 Antibodies
The antibodies with their dilutions and sources were as follows: antibodies for
immunoﬂuorescence: mouse monoclonal anti-HA-tag [1:200; Cell Signaling Technologies (CST; Danvers, MA, USA)], rabbit polyclonal anti-calnexin (CANX, 1: 200;
Santa Cruz Biotechnology, Dallas, TX, USA), Alexa Fluor 568-goat anti-mouse IgG
(1: 200; Molecular Probes, Eugene, OR, USA) and Alexa Fluor 488-goat anti mouse
IgG (1:200, Molecular Probes). For western blotting, the antibodies and their dilutions
are as follows: mouse monoclonal anti-HA-tag [1:1000; Cell Signaling Technologies
(CST; Danvers, MA, USA)], anti-mouse monoclonal antibody [1: 40,000; Cell Signaling Technologies (CST; Danvers, MA, USA)]. As a loading control for western
blot, the following antibodies were used: anti β- actin [1: 1000; Cell Signaling Technologies (CST; Danvers, MA, USA)], Anti-mouse [1: 40,000; Cell Signaling Technologies (CST; Danvers, MA, USA)].
2.2 Generation of E. coli competent cells
The purpose of generating E.coli competent cells is to introduce foreign DNA
or plasmid into a host cell for plasmid amplification (Chang et al., 2017). JEM109 E.
coli cells were generated following Chang et al (2017) protocol.
2.3 Generation of expression mutant constructs using site directed mutagenesis
Mutagenic primers for the selected mutants were designed using Primer X.
pC3-LDLR HA tagged plasmid was kindly provided by Dr. Allaf from Imperial College London. Through sequential site directed mutagenesis, the HA epitope tag was
introduced at the C-terminus of the pC3-LDLR sequence (Kizhakkedath et al., 2019).
According to (Kizhakkedath et al., 2019), two sets of primers listed in Table 2.1 were
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designed and used by Dr. Allaf to introduce the HA tag into the pC3-LDLR sequence.
A set for the first five amino acid codons and another primer set for introducing the
remaining four amino acid codons of the HA tag.

Table 2.1: List of primers used for insertion of C-terminal HA-tag (Kizhakkedath et
al., 2019) and for SDM.
First five amino acid codons in the F: GAG GAT GAC GTG GCG TAC CCA TAC
HA tag

GAT GTT TGA ACA TCT GCC TGG
R: CCA GGC AGA TGT TCA AAC ATC GTA
TGG GTA CGC CAC GTC ATC CTC

Remaining four amino acid codons F: GTA CCC ATA CGA TGT TCC AGA TTA
in the HA tag.

CGC TTG AAC ATC TGC CTG
R: CCA GGC AGA TGT TCA AGC GTA ATC
TGG AAC ATC GTA TGG GTA C

F: Forward primer. R: Reverse primer.

Table 2.2: LDLR variants along with their mutagenic primers.
LDLR mutation Mutagenic primers
p. Cys167Phe

F: 5'CAGCTGTGGGCCTTCGACAACGACCC 3'
R: 5' GGGTCGTTGTCGAAGGCCCACAGCTG 3'

p. Asp178Asn

F: 5' GAAGATGGCTCGAATGAGTGGCCGC 3'
R: 5' GCGGCCACTCATTCGAGCCATCTTC 3'

p. Glu277Lys

F: 5'GTTAATGTGACACTCTGCAAGGGACCCAACAAGTTC 3'
R: 5’GAACTTGTTGGGTCCCTTGCAGAGTGTCACATTAAC 3'
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Table 2.2: LDLR variants along with their mutagenic primers (Continued).
LDLR mutation Mutagenic primers
p. His327Tyr

F: 5' GGCGGCTGTTCCTACGTCTGCAATG 3'
R: 5' CATTGCAGACGTAGGAACAGCCGCC 3'

p. Met652Thr

F: 5' CCCCAGAGGATACGGTTCTCTTCCAC 3'
R: 5' GTGGAAGAGAACCGTATCCTCTGGGG 3'

p. Arg814Gln

F: 5' CTATGGAAGAACTGGCAGCTTAAGAACATCAAC 3'
R: 5' GTTGATGTTCTTAAGCTGCCAGTTCTTCCATAG 3'

F: Forward primer. R: Reverse primer

Site directed mutagenesis was carried out using Pfu Ultra HF polymerase and
the list of primers in Table 2.2 and under the conditions in (Figure 2.1) (Stratagene, La
Jolla, CA, USA).

Figure 2.1: Schematic diagram of PCR conditions for site-directed mutagenesis.

PCR samples were digested with Dpn1 enzyme (Invitrogen) at 37˚C for 4 hours
to eliminate methylated DNA at 37˚C for 4 hours. Transformation was carried out to
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introduce mutants’ DNA into JM109 E. Coli strain to amplify mutated plasmids. Competent cells and dpn1 digested samples were cultured on LB agar (Invitrogen) plates
and were left to grow overnight. After overnight growth, inoculation was performed
and colonies were picked and grown in LB broth overnight. DNA extraction was done
following Qiagen’s miniprep kit protocol and finally the DNA concentration was
measured using NanodropTM 2000/2000c spectrophotometers (Thermofisher).
2.4 Confirmation of the mutagenesis using Sanger DNA sequencing
Generation of LDLR variants was confirmed through Sanger DNA sequencing.
Sequencing was performed using the dideoxy Sanger method by ﬂuorescent automated
sequencing on the ABI 3130xl genetic analyzer (Applied Biosystems, Waltham, MA,
USA).
2.5 Cell culture and transfection using FuGene HD
In this project two immortalized and adherent cell lines were used. HeLa cells
which are cervical cancer cells and Hek293T cells (HEK-293T; ATCC, Manassas, VA,
USA) which are kidney cancer cells. Both cell lines have a similar cell culture protocol
but are used for different purposes. Prior to starting any experiments, everything including Dulbecco’s modiﬁed Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA,
USA) supplied with 10% Fetal Bovine Serum (FBS; invitrogen) and 100 U.ml-1 penicillin/streptomycin at 37°C with 5% CO2. For immunostaining and western blot, HeLa
cells and Hek293T were cultured and maintained. T25 flask (Invitrogen) was used to
maintain both cell lines. The ideal cells confluency is 70% to start with experiments.
70% confluent cells were split by aspirating DMEM using a 5 ml electronic flask. PBS
was used to wash DMEM residue and then cells were trypsinized using Trypsin for 5
minutes at 37˚C in a sterile cell culture incubator. 5 ml DMEM was added to stop the
action of Trypsin and cells were passaged to a new flask containing fresh DMEM.
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2.6 Immunocytochemistry and confocal microscopy and imaging
For immunostaining, coverslips were sterilized using 70% ethanol, absolute
ethanol and UV light. Afterwards, sterilized coverslips were divided into corresponding wells in the 24- well tissue culture plate. 1 ml of HeLa cells were added into each
well containing coverslip and were left to grow for 24 hours. To study the localization
of LDLR, transient transfection was done. 1 ml eppindorf tube for each well was used
to mix 26 µL of Opt i-MEM media (Thermofisher), 1.5 µL FuGene HD transfect ion reagent (Promega, Madison, WI, USA) and 1 µg of HA- tagged wildtype
LDLR wildtype or mutant constructs (Kizhakkedath et al., 2014). GFP-HRas plasmid
was used as a plasma membrane marker and cotransfected with HA-tagged wild-type
or mutant plasmids (Ali et al., 2010). Twenty-four hours after transfection, HeLa cells
that were grown on cover slips in a 24 – tissue culture well plate were washed with
PBS trice, fixed with -20˚C ice cold methanol (Fisher Chemical) for 5 minutes at 20˚C. After that, the fixed cells were washed again with PBS to remove any methanol
residue and then blocking was done using 1% Bovine Serum Albumin (BSA) (Pierce
TM

) two hours at room temperature. After two hours of blocking, HeLa cells were in-

cubated with primary antibodies for 45 minutes at room temperature in mouse monoclonal anti-HA-tag [1: 200; Cell Signaling Technologies (CST; Danvers, MA, USA)]
and rabbit polyclonal anti-calnexin (CANX, 1: 200; Santa Cruz Biotechnology, Dallas,
TX, USA) Afterwards, cells were washed with PBS and incubate with Alexa Fluor
568-goat anti-mouse IgG (1: 200; Molecular Probes, Eugene, OR, USA) and Alexa
Fluor 488-goat anti mouse IgG (1:200, Molecular Probes) secondary antibodies for 45
minutes at room temperature. Finally, cells were mounted on cover slides using (ICN
biomedicals) immunofluor mounting medium. Confocal microscopy and imaging was
performed using Nikon Eclipse system (Nikon instruments Inc) containing FITC and
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TRITC filters. Images were made using 100x oil immersion objective lens, adjusted
and merged using Image J software. All images presented are single sections in the zplane.

2.7 Western blot analysis for glycosylation profile analysis
Cell culture and transfection using FuGene HD
For Western blot, Human embryonic kidney cells (Hek293T) were used. In a
6- tissue culture well plate, transfection was performed using FuGene HD (Promega)
and using 1ug of wild type LDLR plasmid DNA or mutant plasmids. After 48 hours
of transfection, HEK293T cells were washed with PBS, harvested using cell scrappers
(Fisherbrand TM) , collected into Eppendorf tubes and spun using a table centrifuge for
5 minutes at 500 g at 4C. Supernatant containing cell debris was discarded and the
pellet was washed with 800 µL cold PBS and centrifuged again for 5 minutes at 500 g
at 4˚C. The supernatant containing all our protein was taken and stored at -20˚C.

Quantification of protein concentration
Protein estimation was performed using Bicinchoninic Acid Protein Assay
(BCA kit, Pierce). According to BCA kit instructions, 2 mg/ml of stock BSA was prepared and standard dilutions of BSA and RIPA buffer (Thermoscientific TM) were prepared as listed in Table 2.3.
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Table 2.3: Standard dilutions and protein dilutions.
BSA (mg/ml)

BSA (2 mg/ml)

RIPA buffer (µL)

2.0

50

0.0

1.5

37.5

12.5

1.0

25

25.0

0.75

18.8

31.3

0.50

12.5

37.5

0.25

6.3

43.5

0.125

3.1

46.9

0.0

0.0

50.0

Table 2.3 abbreviations: BSA: Bovine Serum Albumin.

After preparing the standards, protein was diluted 5 times with RIPA buffer.
Standard dilution duplicates and protein dilution duplicates were added into designated
wells. 180 µL of mixture A + B were added per well and incubated at 37˚C for 1 hour.
After incubation, the absorbance’s were measured at 562 nm through Tecan Infinite
M200 Pro Microplate reader. The absorbance’s average values were used to draw a
scatter plot along with a trend line equation. Through the trend line equation, the protein concentration was calculated and then multiplied by 5 since it was diluted 5 times
with RIPA buffer. Protein concentration was set at 20 µg. Based on the numbers on
the Excel sheet, the calculations were done and protein samples were prepared. Samples were boiled at 95˚C in a hot well plate for 5 minutes.
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Western blot analysis
After identifying volumes for each mutation, protein was prepared and mixed
well in a cocktail of 5x Lamelli buffer and RIPA buffer. HA-tagged proteins were run
in an 8% acrylamide gel (ThermoFisher) at 90 V which was gradually increased to 120
V. Transfer was done for an hour at room temperature at 60 V using PVDF membrane
(Immobolin). The membrane was washed thrice with TBST each time for 6 minutes
and incubated with respective antibodies. Primary antibody mouse monoclonal antiHA-tag [1:1000; Cell Signaling Technologies (CST; Danvers, MA, USA)] incubation
was done overnight. Secondary antibody anti-mouse monoclonal antibody [1: 40,000;
Cell Signaling Technologies (CST; Danvers, MA, USA)]. PVDF membrane was incubated 1 ml of ECL plus for 5 minutes (ECL plus kit; ThermoFisher

TM)

. Detection

and development was done using Typhoon FLA 9500 imager. B-actin was used as a
loading control, PVDF membrane was incubated with primary antibody anti- β- actin
[1: 1000; Cell Signaling Technologies (CST; Danvers, MA, USA)]. PVDF membrane
was washed trice with TBST each time for 6 minutes then incubated with secondary
antibody anti-mouse monoclonal antibody [1: 40,000; Cell Signaling Technologies
(CST; Danvers, MA, USA)]. PVDF membrane was incubated 1 ml of ECL plus for 5
minutes (ECL plus kit; ThermoFisher

TM)

. Finally, development was done using Ty-

phoon FLA 9500 imager. Images were edited on ImageJ software.
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Chapter 3: Results

The list of the studied missense mutants is shown in Table 3.1 and they were
identified by our collaborators at Imperial College London Diabetes Center in Abu
Dhabi. According to HGMD (Stenson et al., 2014) and LOVD (Fokkema et al., 2011),
(p. Cys167Phe) is the only novel variant. However, they have been all classified as
potentially “disease causing” but further evidence was needed.

Table 3.1: List of LDLR missense mutants studied for the purpose of this thesis.
Coding position

Protein position

c. 500G>T

p. Cys167Phe

c. 532G>A

p. Asp178Asn

c. 829G>A

p. Glu277Lys

c. 940G>A

p. Gly314Arg

c. 979C>T

p. His327Tyr

c. 1956 G>C

p. Met652Thr

c. 2441 G>A

p. Arg814Gln

3.1 All mutants were generated and sequenced
Site directed mutagenesis was performed to generate the desired mutants using
pC3- LDLR HA tagged wild type plasmid as template (Kizhakkedath et al., 2019). The
template plasmid has kindly been provided by Dr. F. Allaf from Imperial College London. The LDLR missense mutations: (p. Cys167Phe), (p. Asp178Asn), (p.
Glu277Lys), (p. Gly314Arg), (p. His327Tyr), (p. Met652Thr) (p. Arg814Gln) were
successfully generated through site directed mutagenesis using the list of primers in
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Table 2.1.
Sanger DNA sequencing was performed to confirm the successful generation
of the desired mutants. The sequencing chromatograms and protein sequence alignments using Clustal Omega of all the generated mutants are shown in Figures (3.13.7).

Figure 3.1: Sequence chromatogram and alignment of mutant c.500 G>T; p.
Cys167Phe.
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Figure 3.2: Sequence chromatogram and alignment of mutant c.532 G>A; p.
Asp178Asn.

Figure 3.3: Sequence chromatogram and alignment of mutant c.829 G>A; p.
Glu277Lys.
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Figure 3.4: Sequence chromatogram and alignment of mutant c.940G>A; p.
Gly314Arg.

Figure 3.5: Sequence chromatogram and alignment of mutant c.979 C>T; p.
His327Tyr.
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Figure 3.6: Sequence chromatogram and alignment of mutant c.1956T>C; p.
Met652Thr.

Figure 3.7: Sequence chromatogram and alignment of mutant c.2441G>A; p.
Arg814Gln.
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3.2 The missense mutations (p. Cys167Phe), (p. Asp178Asn), (p. His327Tyr) and
(p. Met652Thr) seem to affect the trafﬁcking and cell surface expression of
LDLR
After successfully generating mutated LDLR constructs through site directed
mutagenesis, immunocytochemistry was performed to investigate the expression and
subcellular localization of the seven generated LDLR constructs at the cellular level.
HeLa cells were co-transfected with EGFP-Ras plasmid which been used previously
in the laboratory as a plasma membrane marker (Kizhakkedath et al., 2019) along with
the wild type or the seven LDLR mutants individually. As predicted, the wild-type
LDLR receptor was found to be localized to the plasma membrane as conﬁrmed by its
co-localization with GFP-H-Ras (Figure 3.8, panels A(iii)). On the other hand, out of
the seven LDLR variants tested, (p. Glu277Lys), (p. Gly314Arg) and (p. Arg814Gln)
were found to have a similar localization to the wild-type and were found to be exclusively localized to the plasma membrane and were confirmed by their co-localization
with the EGFP- HRas as displayed in (Figure 3.8 panels D (iii), E (iii) and H (iii))
respectively. Also, it was further confirmed that (p. Glu277Lys), (p. Gly314Arg) and
(p. Arg814Gln) failed to co-localize with Calnexin which is an endogenous protein
expressed exclusively in the ER and therefore has been used as an ER marker confirming that (p. Glu277Lys), (p. Gly314Arg) and (p. Arg814Gln) are plasma membrane
retained in (Figure 3.9 panels D (iii), E (iii) and H (iii)) respectively.
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Figure 3.8: Hela cells were grown on sterile coverslips for 24 hours and transiently
co transfected with HA-tagged LDLR plasmids and GFP tagged HRAS plasmid using FuGene transfection reagent and stained with anti-HA antibodies.
The first horizontal panel (i) illustrates the fluorescent staining and expression of HA-tagged LDLR
(ii) shows Hela cells expressing the GFP-HRas fluorescent signal (iii) shows the merged images of (i)
and (ii) illustrating the co-localization of HA tagged LDLR and GFP HRas. GFP HRas was used as a
plasma membrane marker. Images were captured via Nikon confocal microscopy at 100x and merged
through Image J software.
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Figure 3.8: Hela cells were grown on sterile coverslips for 24 hours and transiently
co-transfected with HA-tagged LDLR plasmids and GFP tagged HRAS plasmid using FuGene transfection reagent and stained with anti-HA antibodies (Continued).
The first horizontal panel (i) illustrates the fluorescent staining and expression of HA-tagged LDLR
(ii) shows Hela cells expressing the GFP-HRas fluorescent signal (iii) shows the merged images of (i)
and (ii) illustrating the co-localization of HA tagged LDLR and GFP HRas. GFP HRas was used as a
plasma membrane marker. Images were captured via Nikon confocal microscopy at 100x and merged
through Image J software.

Furthermore, the other FH-associated LDLR mutants (p. Cys167Phe), (p.
Asp178Asn), (p. His327Tyr) and (p. Met652Thr) were found to be localized intracellularly as seen in (Figure 3.9 panels B (iii), C (iii), F (iii) and G (iii)) respectively. The
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intracellular localization of those mutants was confirmed through there co-localization
with Calnexin. None of those mutants showed any significant co-localization with the
EGFP-HRas as apparent in (Figure 3.8 panels B (iii), C (iii), F (iii) and G (iii)).

Figure 3.9: Hela cells were grown on sterile coverslips for 24 hours and transiently
transfected with HA-tagged LDLR plasmids using FuGene transfection reagent and
stained with anti-HA antibodies and anti- Calnexin (Calx) antibodies.
The first vertical panel (i) shows the fluorescent staining of HA-tagged LDLR (ii) shows the fluorescent staining of Calnexin (Calx) in HeLa cells (iii) shows the merged images of (i) and (ii) illustrating
the co-localization of HA tagged LDLR with the Calnexin (Calx) used as the ER marker. Images were
captured through Nikon confocal microscopy at 100x and merged through Image J software.
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Figure 3.9: Hela cells were grown on sterile coverslips for 24 hours and transiently
transfected with HA-tagged LDLR plasmids using FuGene transfection reagent and
stained with anti-HA antibodies and anti- Calnexin (Calx) antibodies (Continued).
The first vertical panel (i) shows the fluorescent staining of HA-tagged LDLR (ii) shows the fluorescent staining of Calnexin (Calx) in HeLa cells (iii) shows the merged images of (i) and (ii) illustrating
the co-localization of HA tagged LDLR with the Calnexin (Calx) used as the ER marker. Images were
captured through Nikon confocal microscopy at 100x and merged through Image J software.

3.3 FH associated LDLR mutants have preserved glycosylation profiles
The LDLR mutants were subjected for western blot to study their glycosylation
profiles. As mentioned in the introduction, mature LDLR is glycosylated in the ER
and consists of O-linked and N-linked glycosylation. A mature LDLR will present to
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migrating bands in an immunoblot. A slow migrating 160 kDa band and a slower migrating 120 kDa band. 160 kDa represents mature LDLR and 120 kDa represents precursor LDLR. Using an anti-HA tag, we were able to observe migrating LDLR in
western blot (Figure 3.10). Evidently, wild-type LDLR displayed two migrating bands,
mature LDLR and precursor LDLR. The negative control showed no bands which is
considered as a good sign indicating there were no non-specific binding of antibodies.
(p. Asp482His) is an ER retained LDLR mutant that was previously studied by (Kizhakkedath et al., 2019). (p. Asp482His) used here as a positive control. LDLR mutants (p. Cys167Phe), (p. Asp178Asn), (p. Glu277Lys), (p. Gly314Arg), (p.
His327Tyr), (p. Met652Thr) and (p. Arg814Gln) all displayed two migrating bands.
However, (p. Cys167Phe) and (p. Met652Thr) bands appeared faint.

Figure 3.10: Western blot results of the wildtype, (-) control (Untransfected), p.
Asp482His (+) control, (p. Cys167Phe), (p. Asp178Asn), (p. Glu277Lys), (p.
Gly314Arg), (p. His327Tyr), (p. Met652Thr), (p. Arg814Gln).
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Chapter 4: Discussion
FH is an inherited form of FH affecting 1 in 250 and often is caused by variants
(mutation) in the LDLR gene. Hypercholesterolemia is highly prevalent in the UAE
affecting about 25% of the Emirati population. Often this condition runs in Emirati
families suggesting an inherited aspect but the underlying cause have not been yet
identified. LDLR variants were identified by Imperial College in Emiratis with suspected FH. The identified variants affect the various known LDLR domains (Figure
4.1). Therefore, in this thesis, the impact of seven of those variants on the cellular
behavior of the receptor were evaluated.

Figure 4.1: Schematic diagram of the five structural domains and the location of the
studied LDLR variants. Adapted and modified from Rodríguez-Jiménez et al. (2019).

Some of the generated LDLR genetic variants have been reported to cause familial hypercholesterolemia (FH). Among those variants (Figure 4.1), two of them are
located at exon 4 in the ligand binding domain of the LDLR (p. Cys167Phe) and (p.
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Asp178Asn). Also, another two variants (p. Glu277Lys) and (p. Gly314Arg) were
found to be located at exon 6 in the ligand binding domain of the LDLR. The rest of
the mutants (p. His327Tyr), (p. Met652Thr) and (p. Arg814Gln) were found to be located at exons 7, exon 13 and exon 17, respectively.
It has been reported that (p. Cys167Phe) is a novel mutation but (p.
Asp178Asn) has been reported before by HGMD (Stenson et al., 2014) and LOVD
(Fokkema et al., 2011). However, both variants have been reported as disease causing.
The ligand binding domain (LBD) of the LDLR plays a role in the stability of the
LDLR structure. The LBD consists of 40 residues with six conserved cysteine amino
acids. At the C terminus of each LR, there are a group of negatively charged amino
acids (Ser-Asp-Glu) that interact with positively charged amino acid residues on apoB
and apoE. According to our results, both (p. Cys167Phe) and (p. Asp178Asn) were
expressed on the plasma membrane and were expressed intracellularly. We predicted
that a substitution in Cys to Phe at position 167 and a change in Asp to Asn at position
178 cause altered LDL-LDLR binding capacity. However, (p. Asp178Asn) showed a
high expression while (p. Cys167Phe) showed a low LDLR expression on the immunoblot. According to a mutational analysis done by (Esser et al., 1988), LR3- LR7
are required for maximal binding of LDL and LDLR. Variants (p. Glu277Lys) and (p.
Gly314Arg) are located at exon6 in the ligand binding domain in LDLR. Variant (p.
Glu277Lys) was first reported and identified in Swedish children for the first time
(Ekstrom, Abrahamson, Sveger, Lombardi, & Nilsson‐Ehle, 1995). The substitution
of glutamic acid which is an acidic amino acid to Lysine which is a basic amino acid
alters the protein folding of LDLR since Asp and Glu are negatively charged residues
and are important in coordinating calcium ions and their interactions with cystienes
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forming disulphide bridges (Uribe et al., 2018) (Rodríguez-Jiménez et al., 2019). Variant p. Gly314Arg located at exon 6 and is caused by a change in the last nucleotide of
exon 6 (G>A at 940). Glycine is present in the epidermal growth factor domain (EGF)
and is located beside a threonine. However, according to (Usifo et al., 2012), they
predicted that the binding affinity of calcium ion can be altered if glycine was substituted with an arginine and through there in-silico analysis and they discovered that this
variant has no evidence of pathogenicity (Usifo et al., 2012). However, according to
HGMD (Stenson et al., 2014) and LOVD (Fokkema et al., 2011), it was classified as
“disease causing”. Moreover, variant (p. His327Tyr) affects the EGF-A domain. As
mentioned in the introduction, EGF-A interacts with proprotein convertase subtilisin/kexin type 9 (PCSK9) which plays a role in regulating LDLR homeostasis. A mutation in this domain can further induce PCSK9’s activity and lead to an increase
LDLR catabolism (Jelassi et al., 2009). As illustrated through confocal images, some
of it is found to be localized mainly in the cytoplasm where it gets degraded by PCSK9.
Mutation (p. Met652Thr) is found in the β-propeller region made up of YWTD repeats
separating EGF-A and EGF-B repeats from EGF-C repeat. The mutant has shown intracellular retention in HeLa cells in the confocal images and was slightly expressed
in the immunoblot. The EGF domain is implicated in the release of the LDL- LDLR
complex in the endosome due to pH change. Lastly, mutation (p. Arg814Gln), located
at exon 17 encoding for the intracellular cytoplasmic domain of the LDLR. The cytoplasmic domain is extremely important in the release of modified LDLR from the ER
(Rodríguez-Jiménez et al., 2019). It showed co-localization with EGFP-HRas and
showed high LDLR expression.
Positive control (p. Asp482His) was previously studied by (Kizhakkedath et
al., 2019). The substitution of Asp to His at position 482 caused retention in the ER
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and affected the trafficking of LDLR to the cell surface. According to functional analysis and studies, ER retained mutants induce ER stress which activate unfolded protein
response (UPR). The misfolded proteins become substrates for ER-associated degradation (ERAD). When ERAD fails to degrade misfolded proteins and get inactivated,
it induces unfolded protein response (UPR). In the ER, inositol- requiring enzyme acts
as a stress sensor and is activated when there are increased levels of ER stress (Kizhakkedath et al., 2019). When UPR is activated, it reduces ER stress by increasing
expression of stress alleviating genes and catalyzes the splicing of the mRNA of the
transcription factor X-box binding protein (XBP-1) (Kizhakkedath et al., 2019). Further studies are now needed to further analyze the effects of these mutants.
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Chapter 5: Conclusion

5.1 Summary
To summarize, seven LDLR Emirati variants were generated and their expression and co-localization was studied suggesting partial retention in the ER for some of
them. According to the results of transfected Hek293T on the immunoblot, evidently,
the wild type showed the highest expression. Similarly, (p. Glu277Lys) and (p.
His327Tyr) showed an almost similar expression to the wildtype. On the other hand,
(p. Asp178Asn) and (p. Arg814Gln) showed an intermediate expression unlike (p.
Cys167Phe) and (p. Met652Thr) who showed the weakest expression on the immunoblot.
5.2 Future experiments
Internalization assays must be run in the future to further elucidate and determine the functionality, the binding capacity and classification of those mutants. Triton
X solubility assay and quantitative PCR (qPCR) could be done in the future to measure
the expression of XBP-1 for LDLR mutants. Endoglycosidase H sensitivity assay
could be performed to further study the glycosylation status of these mutants. Also, a
number of chaperons found in the ER that are associated with LDLR could be used to
further study ER retained mutant’s interactions and compare it to the wildtype using
multiple ER resident chaperons CANX/calreticulin system and the GRP78/GRP94
system. The identified LDLR mutants could be further investigated in other cell lines
such as HepG2 cell lines which could be a better cellular model to study and present
familial hypercholesterolemia and its phenotype since FH occurs in the liver. Another
possible future experiment is to study LDLR mutants on LDLR knockout cell lines.
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Knockout cell lines are generated through removing endogenous LDLR and substituting it with the exogenous mutated LDLR gene. In this way, knockout cell lines will
help us know if the results obtained from experiments are from the exogenous LDLR
mutated form.
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